Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression

Brazilian Journal of Medical and Biological Research

Volumn 38, Issue 11, 2005, Pages 1609-1613

  Ribas, C ^a   Colleoni, G W B ^a   Almedia, M S S ^a   Aguiar, K C C ^a   Silva, M R R ^a   Bordin, J O ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiogenesis; Multiple myeloma; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MULTIPLE MYELOMA; PLASMA CELL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 27944503430     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2005001100007     Document Type: Article

References (12)

1. Rajkumar SV, Mesa RA, Fonseca R et al. (2002). Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clinical Cancer Research, 8: 2210-2216.
2. Pruneri G, Ponzoni M, Ferreri AJM et al. (2002). Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. British Journal of Haematology, 118: 817-820.
3. Sezer O, Niemoller K, Eucker J et al. (2000). Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Annals of Hematology, 79: 574-577.
4. Bellamy WT, Richter L, Frutiger Y et al. (1999). Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Research, 59: 728-733.
5. Bellamy WT (2001). Expression of vascular endothelial growth factor and its receptor in multiple myeloma and other hematopoietic malignancies. Seminars in Oncology, 28: 551-559.
6. Paydas S, Zorludemir S, Baslamisli F et al. (2002). Vascular endothelial growth factor (VEGF) expression in plasmacytoma. Leukemia and Lymphoma, 43: 139-143.
7. Greipp PR, Leong T, Bennett JM et al. (1998). Plasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report. Blood, 91: 2501-2507.
8. Rajkumar SV, Fonseca R, Lacy MQ et al. (1999). Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. Journal of Clinical Oncology, 17: 1551-1557.
9. Bartl R, Frisch B, Fateh-Moghadam A et al. (1987). Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. American Journal of Clinical Pathology, 87: 342-355.
10. Kumar S, Fonseca R, Dispenzieri A et al. (2003). Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood, 101: 1715-1717.
11. Vacca A, Ribatti D, Presta M et al. (1999). Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93: 3064-3073.
12. Schey SA, Fields P, Bartlett JB et al. (2004). Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. Journal of Clinical Oncology, 22: 3269-3276.